Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Sullivan

Neurology with Special Qualifications in Child Neurology San Francisco, CA Medical Doctor

NPI 1952321135 CMS profile 732083

400 Parnassus Ave Fl 8, Box 0348, San Francisco, CA 94143

Open in the dashboard

General payments

$240,138

118 records reported · program years 2019–2025

Research payments

$1,949

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,464,835 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Joseph Sullivan of San Francisco, CA is reported in the CMS Open Payments database as having received $240,138 across 118 general payments and $1,949 in research payments paid to them. Separately, studies naming them as principal investigator received $1,464,835 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $111,729 37
2024 General $66,434 28
2023 General $30,784 22
2023 Research $1,949 5
2022 General $6,219 8
2021 General $7,275 7
2020 General $12,802 11
2019 General $4,895 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Sullivan
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Joseph Sullivan were reported at $111,729. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Joseph Sullivan Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $4,895 $262 $68–$1,313 $163
2020 $12,802 $188 $46–$1,222 $114
2021 $7,275 $183 $45–$1,356 $132
2022 $6,219 $229 $72–$1,177 $149
2023 $30,784 $269 $93–$1,195 $160
2024 $66,434 $300 $98–$1,428 $164
2025 $111,729 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ceribell, Inc. $96,200 20 payments
  2. Biocodex, Inc. $53,916 24 payments
  3. Ucb SA $26,238 8 payments
  4. UCB, Inc. $23,329 23 payments
  5. Jazz Pharmaceuticals Inc. $13,048 9 payments
  6. Greenwich Biosciences, Inc. $9,672 6 payments
  7. Zogenix Inc. $4,710 3 payments
  8. BTG International, Inc. $2,903 4 payments
  9. Biogen, Inc. $2,500 1 payment
  10. Marinus Pharmaceuticals, Inc. $1,963 5 payments
  11. Other $5,660 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $200,180 61 payments
  2. Travel and Lodging $25,443 14 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,810 4 payments
  4. Honoraria $3,995 2 payments
  5. Food and Beverage $3,697 36 payments
  6. Education $13 1 payment
Products named General payments · program years 2019–2025
  1. POCKET EEG DEVICE $82,440 19 payments
  2. DIACOMIT $53,916 24 payments
  3. Fintepla Neurology $31,993 27 payments
  4. Ceribell Rapid Response EEG $13,760 1 payment
  5. Epidiolex $13,742 10 payments
  6. Fintepla Treatment of seizures $4,710 3 payments
  7. Fycompa $1,680 1 payment
  8. Brineura $1,600 1 payment
  9. ZTALMY $602 2 payments
  10. VNS THERAPY SENTIVA MODEL 1000 GENERATOR $228 2 payments
  11. Other $190 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $1,949 5 payments

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record